Mutasjonstesting ved ikke-småcellet lungekreft

Tidsskrift for den Norske Laegeforening

Volumn 132, Issue 8, 2012, Pages 952-955

  Brustugun, Odd Terje ^a,b   Helland, Åslaug ^a,b   Fjellbirkeland, Lars ^a,b   Kleinberg, Lilach ^c   Ariansen, Sarah ^c   Jebsen, Peter ^c   Scott, Helge ^b,c   Dønnem, Tom ^d,e   Bremnes, Roy ^d,e   Berg, Thomas ^d   Grønberg, Bjørn Henning ^f,g   Dai, Hong Yan ^f   Wahl, Sissel Gyrid Freim ^f   Mangseth, Kjersti ^h   Helgeland, Lars ^h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Oslo universitetssykehus ^*  (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; COMPARATIVE STUDY; EXON; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERSONALIZED MEDICINE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENES, ERBB-1; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84865302915     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.11.1017     Document Type: Article

References (20)

1. Cancer in Norway. 2009. Oslo: Kreftregisteret, 2011. www.kreftregisteret.no/no/Generelt/Publikasjoner/Cancer-in-Norway/Cancerin-Norway-2009/ (21.3.2012).
2. Sagerup CM, Småstuen M, Johannesen TB et al. Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax 2011; 66: 301-7.
3. Helbekkmo N, Sundstrøm SH, Aasebø U et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97: 283-9.
4. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
5. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
6. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
7. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
8. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009; 361: 1018-20.
9. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
10. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
11. Rosell R, Carcereny E, Gervais R et al.. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
12. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
13. Sharma SV, Bell DW, Settleman J et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-81.
14. Helland Å, Skaug HM, Kleinberg L et al. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol 2011; 6: 947-50.
15. Miyamae Y, Shimizu K, Hirato J et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011; 25: 921-8.
16. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67.
17. Den norske patologforening. EGFR-ny anbefaling om rutine ved all ikke-småcellet lungekreft. www.legeforeningen.no/id/167991.0 (5.2.2012).
18. Edwards SL, Roberts C, McKean ME et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the nonsmall cell category. J Clin Pathol 2000; 53: 537-40.
19. Planchard D, Loriot Y, Goubar A et al. Differential expression of biomarkers in men and women. Semin Oncol 2009; 36: 553-65.
20. Pirker R, Herth FJ, Kerr KM et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010; 5: 1706-13.